Cardiac management in women receiving chemioterapy for breast cancer;Valutazione e monitoraggio cardiovascolare nelle donne in chemioterapia per carcinoma mammario

Annali Degli Ospedali San Camillo e Forlanini

Volumn 12, Issue 5, 2010, Pages 10-17

  Boccardi, Lidia ^a   Minardi, Giovanni ^a   Pino, Paolo Giuseppe ^a   Pulignano, Giovanni ^a   Manzara, Carla ^a   Leonetti, Stefania ^a   Bernardi, Leda ^a   Parisi, Anna Maria ^b   Capristo, Costanza ^b  

^a Dipartimento Cardiovascolare   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Anticancer drugs; Breast cancer; Cardiotoxicity; Echocardiography

Indexed keywords

EID: 79955058516     PISSN: 11274867     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Colditz GA, Willet WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316: 1105- 10
2. DeNino WF, Tchernof A, Dionne IJ, et al. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healty non-obese women. Diabetes care 2001; 24: 925-32
3. Mercuro G, Zoncu S, Saiu, et al. Menopause induced by ovophorectomy reveals a role of ovarian estrogen on the maintenance of pressure homeostasis Maturitas 2004; 47: 131-8
4. Travis LB, Rabkin CS, Brown LM, et al. Cancer sourvivor-ship. Genetic susceptibility and second primary cancers: Research Strategies And Reccomendations. J Natl Cancer Inst 2006; 98: 15-25
5. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac acverse effects in the Herceptin adjuvant trial. JCO 2007; 25: 3859-65
6. Jones LW Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007; 50: 1435-41 Epub 2007; Sep 24. Review
7. Takamura G, Fujwara H. Doxorubicin-induced cardiomyopathy. From the cardiotoxic mechanisms to management. Progr. Cardiovasc Dis 2007; 49: 330-352
8. Force T, Krause TS, Van Etten RA. Molecular mechanism of cardiotoxicity of tyrosine kinase inhibition. Nature Rewiews. Cancer 2007; 7: 332-44
9. Von Hoff DD, Layard MV, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-17
10. The Italian Multicenter Breast Study with epirubicin. Phase III randomized study of fluoruracil, epirubicin, and cyclophosphamide in avancated breast cancer: an talian multicenter trial. J Clin Oncol 1988; 6: 976-982
11. Bonneterre J, Roché H, Kerbat P, et al. Longterm cardiac follow-up in relapse-free patients after six courses of fluoruracil, epirubicin, cyclophosphamide, with either 50 o 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group JClinic Oncol 2004; 22: 3070-79
12. Mackey JR, Clemons M, Còté MA, et al. Cardiac managment during adjuvant trastuzumab the reccommendations of the Canadian Trastuzumab Worki. Curr Oncol 2008; 15: 24-35
13. Pai VB, Nahata MC. Cardiotoxicity of chemioterapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22: 263-302
14. Manistry C, Francis DP. Ejection fraction: a measure of desperation? Heart 2008; 94: 446-50
15. Giorgi M, Fava A, Lewis M, et al. Trastuzumab cardiotoxicity in advanced breast cancer patients: a single institution experience. Abstract 208 Euroecho 2008, Eur J Echocard 2008; 9 suppl 1, S11
16. Radulescu D, Buzdugan E, Stoicescu L, et al. Do angiotensin converting enzyme inhibitors prevent the epirubucin induced cardiotoxicity in cancer patients? Abstract 209 Euroecho 2008, Eur J Echocard 2008; 9 suppl 1, S11
17. Prosnitz RG, Chen YH, Marks LB. Cardiac Toxicity following thoracic radiation. Sem Onc 2005; 32(suppl3): s71-s80
18. Dolci A, Dominici R, Cardinale D, et al. I marcatori biochimici nella valutazione della cardiotossicità da farmaci antineoplastici:analisi sistematica della letteratura e raccomandazioni per il loro utilizzo. G Ital Cardiol 2006; 7(9): 604-11
19. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemioterapy. Circulation 2004; 109: 2749-54
20. Van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving antthracyclines The Cochane Colaboration 2008; 1: 1-50
21. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection in women receiving epirubicin chemioterapy for avanced breast cancer. J Clin Oncol 1996; 14: 362-72
22. Lang RM, Bierig M, Devereux RB, et al. Reccomendations for chamber quantification. Eur J Echocard 2006; 7: 79-108
23. The Task Force on Heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure Eur Heart J, 2005; 26: 1115-40